UBT251
No brand name yet
A once weekly triple agonist from The United Laboratories, licensed to Novo Nordisk outside Greater China in March 2025. Phase 3 diabetes trials began in China in September 2026.
UBT251 comes from The United Laboratories International and sits in the Incretins class on the board. Route: weekly injection. Use tracked here: Type 2 diabetes and obesity, with phase 3 diabetes and obesity trials in China. It stands at Phase 3 on the board, with 1 news move logged; the latest is dated 26 Oct 2026.
- 05ApprovedCleared for sale in at least one major market for this use.
- 04FiledApplication submitted to a regulator and under review.
- 03Phase 3Here now
- 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
- 01Phase 1First doses in people. Safety, dose range, how the body handles it.
- Company
- The United Laboratories Internationalwith Novo Nordisk
- Mechanism
- Single peptide agonist of the GLP-1, GIP and glucagon receptors
- Given as
- weekly injection
- Lead use on the board
- Type 2 diabetes and obesity, with phase 3 diabetes and obesity trials in China
- Moves logged
- 1latest 7 days ago
UBT251 news moves
-
UBT251 phase 2 diabetes data reach Cell Metabolism as China phase 3 runs
The peer reviewed paper confirms the March topline for the GLP 1, GIP and glucagon triple agonist: up to 2.16 points off HbA1c and up to 9.8 percent off body weight at 24 weeks. Two phase 3 diabetes trials in China are already dosing.
Other incretins molecules on the board, with their current stage.